MAP4K4-IN-3

• Description :

  MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  MAP4K

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/map4k4-in-3.html

• Purity :

  99.15

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  NC1=NC=C(C2=CC(C3=CC=C(Cl)C=C3)=C(N)N=C2)C=N1

• Molecular Formula :

  C15H12ClN5

• Molecular Weight :

  297.74

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Ammirati M, et al. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based AntidiabeticTreatment. ACS Med Chem Lett. 2015 Oct 6;6 (11) :1128-33.|[2]Dow RL, et al. 2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety. J Med Chem. 2018 Apr 12;61 (7) :3114-3125.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  MAP4K4/HGK

• CAS Number :

  [1811510-58-3]